Dr Khurum Khan

University College London Hospitals

Dr Khurum Khan is a research-active consultant who trained in medical oncology at the Northern Ireland Cancer Centre and Royal Marsden NHS Foundation Trust London. He studied mechanisms of response and resistance to targeted therapies in advanced colorectal cancer and gained MD(Res) degree under supervision of Professor David Cunningham at the Institute of Cancer Research and the Royal Marsden Hospital. He was involved in setup and conduct of large multicentre academic and translational studies from the time that he spent in full-time research, which included working as trial physician for phase II/III studies in early and advanced gastrointestinal cancers.

In collaboration with Professor Cunningham, Dr Khan secured funding from industry to run an academic phase II study of a multikinase inhibitor in metastatic refractory colorectal cancer. He also wrote a successful application for NIHR portfolio adoption of this study.

Dr Khan is a consultant in Gastrointestinal Oncology at UCLH and attends NMUH. He is also the Clinical Lead of Carcinoma of Unknown Primary (CUP) at NMUH. He is actively involved in translational research and has presented and lectured in international conferences and public forums respectively. Dr Khan published several high impact papers in peer-reviewed journals including Science, Cancer Discovery, Gut, Gastroenterologist, Clinical Cancer Research, Oncogene, Oncologist, BMC Cancer, and British Journal of Cancer. He served as expert member of National Research and Ethics Committee.

Dr Khan has also played an active role in improving the educational experience of the junior doctors nationally. He writes questions for MRCP(UK) and Medical Oncology exams, and remains part of the national medical oncology recruitment panel.

dont miss

Translational research in GI Oncology- how to make progress?

Personalized medicine has made serious inroads in management of cancer patients across different cancer types; however, the progress in GI malignancies has rather reached a plateau in last decade or so. This talk will highlight how to design clinical trials in a cost-effective but scientifically meaningful way such that clinical outcomes can be optimized.

EVEN MORE SEMINARS

  • Chris Carrigan: Speaking at the Oncology Convention

    Chris Carrigan
    Bowel Cancer Intelligence UK

    Patient Engagement in the uses of Patient Data

  • Malcolm Wilson: Speaking at the Oncology Convention

    Malcolm Wilson
    The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester

    Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours

  • Professor Robert Thomas: Speaking at the Oncology Convention

    Professor Robert Thomas
    Bedford and Addenbrooke's Cambridge University Hospitals

    Evidence based lifestyle strategies after cancer - a research review

  • Dr Khurum Khan: Speaking at the Oncology Convention

    Dr Khurum Khan
    University College London Hospitals

    Translational research in GI Oncology- how to make progress?

  • Dr Abeer Shaaban: Speaking at the Oncology Convention

    Dr Abeer Shaaban
    Queen Elizabeth Hospital Birmingham & University of Birmingham

    Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations